GlycoMimetics Total Non-Cash Items 2012-2025 | CBIO
GlycoMimetics total non-cash items from 2012 to 2025. Total non-cash items can be defined as the total of all non-cash charges adjusting Net Income on the Cash Flows Statement
GlycoMimetics Annual Total Non-Cash Items
(Millions of US $) |
| 2024 |
$6 |
| 2023 |
$5 |
| 2022 |
$5 |
| 2021 |
$7 |
| 2020 |
$8 |
| 2019 |
$7 |
| 2018 |
$5 |
| 2017 |
$4 |
| 2016 |
$3 |
| 2015 |
$3 |
| 2014 |
$2 |
| 2013 |
$1 |
| 2012 |
$1 |
| 2011 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.009B |
$0.000B |
|
GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States.
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
| OncoCyte (IMDX) |
United States |
$0.090B |
0.00 |
